Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Immunomedics, Inc., announced that 9 presentations, of which 7 are oral presentations, will be given at the 58th Annual Meeting of the Society of Nuclear Medicine (SNM 2011), scheduled for June 4 – 8, 2011, in San Antonio, TX.

Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, announced that 9 presentations, of which 7 are oral presentations, will be given at the 58th Annual Meeting of the Society of Nuclear Medicine (SNM 2011), scheduled for June 4 – 8, 2011, in San Antonio, TX.

Four of the oral presentations will be to provide updates on clinical trials involving the Company's proprietary monoclonal antibodies, highlighted by the Phase Ib/II study with yttrium-90-labeled (90Y) clivatuzumab in combination with gemcitabine as a frontline therapy in patients with previously untreated advanced pancreatic cancer. First results from an investigator-sponsored study of TF2, a bispecific antibody constructed using the patented Dock-and-Lock technology that targets the carcinoembryonic antigen (CEA), for pretargeted radiation therapy of patients with colorectal cancer will also be presented.

The French study group, GOELAMS, will report interim efficacy results from their multicenter, Phase II study of 90Y-epratuzumab as a consolidation therapy in aggressive non-Hodgkin's lymphoma.  The final clinical study to be updated at this year's SNM meeting will be on pretargeted radioimmunotherapy in progressive medullary thyroid cancer using a bispecific antibody derived from labetuzumab, the Company's humanized anti-CEA antibody.

The schedule and meeting places for the oral presentations and scientific poster sessions, together with the publication numbers, are listed below:

• "Pretargeted radioimmunotherapy (pRAIT) in progressive medullary thyroid cancer (MTC)" [Publication No. 125, Scientific Paper Session (Oral), Session Info: Endocrinology: Neuroendocrine Tumors (Integrated Session), Monday, June 6, 10:36 a.m. – 10:48 a.m., Room 214A]
• "Targeting GRPR-expressing tumors with an 18F-labeled bombesin analog" [Publication No. 297, Scientific Paper Session (Oral), Session Info: Novel Radioactive Probes II: Tumor Probes – Part 1, Tuesday, June 7, 9:00 a.m. – 9:12 a.m., Room 214BC]
• "Consolidation anti-CD22 fractionated radioimmunotherapy (RIT) with 90Y-epratuzumab tetraxetan following R-CHOP in elderly diffuse large B-cell lymphoma (DLBCL) patients" [Publication No. 355, Scientific Paper Session (Oral), Session Info: Radiopharmaceutical Therapy II: Radioimmunotherapy, Tuesday, June 7, 9:45 a.m. – 9:57 a.m., Room 217B]
• "Fractionated radioimmunotherapy with 90Y-clivatuzumab tetraxetan (90Y-hPAM4) plus gemcitabine (Gem) in advanced pancreatic cancer (APC)" [Publication No. 357, Scientific Paper Session (Oral), Session Info: Radiopharmaceutical Therapy II: Radioimmunotherapy, Tuesday, June 7, 10:09 a.m. – 10:21 a.m., Room 217B]
• "Phase I clinical study of the feasibility of pretargeted radioimmunotherapy (PT-RAIT) in patients with colorectal cancer (CRC): First results" [Publication No. 358, Scientific Paper Session (Oral), Session Info: Radiopharmaceutical Therapy II: Radioimmunotherapy, Tuesday, June 7, 10:21 a.m. – 10:33 a.m., Room 217B]
• "A rapid method for F-18 labeling of proteins for PET " [Publication No. 572, Scientific Paper Session (Oral), Session Info: Novel Radioactive Probes III: Labeling Methods and Others, Wednesday June 8, 9:45 a.m. – 9:57 a.m., Room 214BC]
• "Evaluation of 1,4,7-triazacyclononane-1,4-diacetate (NODA) ligand for the development of PET imaging agents" [Publication No. 577, Scientific Paper Session (Oral), Session Info: Novel Radioactive Probes III: Labeling Methods and Others, Wednesday June 8, 10:45 a.m. – 10:57 a.m., Room 214BC]
• "A facile kit for F-18 radiolabeling of peptides for PET " [Publication No. 1489, Scientific Poster Session, Poster Section: Novel Radioactive Probes Posters, Monday June 6, 2:30 p.m. – 4:00 p.m., Exhibit Hall B]
• "Pretargeting of prostate cancer with an internalizing anti-EGP-1 x anti-HSG bispecific antibody" [Publication No. 1680, Scientific Poster Session, Poster Section: Basic Science Posters (Oncology), Tuesday, June 7, 2:30 p.m. – 4:00 p.m., Exhibit Hall B]

Source: Immunomedics